Moderna COVID drug
The Latest
-
Kids Are Next: Moderna Begins COVID-19 Vaccine Clinical Trials On Children
The clinical trial will enroll around 6,750 children in the U.S. and Canada. 
The clinical trial will enroll around 6,750 children in the U.S. and Canada. -
Moderna Boss Says Its COVID Vaccine Offers Long-Term Protection
There are lingering questions about how the vaccine can provide a safe and effective level of immunity and how long it will last. 
There are lingering questions about how the vaccine can provide a safe and effective level of immunity and how long it will last. -
Moderna Trial Aims To Get Students Back In The Classroom In 2021
Moderna is one of two pharmaceutical companies that applied for the FDA go ahead for a COVID vaccine. 
Moderna is one of two pharmaceutical companies that applied for the FDA go ahead for a COVID vaccine. -
Moderna Seeks Authorization In U.S., UK; Reports 94% Efficacy Rate
The results follow the 94.5% efficacy rate that the Massachusetts-based pharma reported two weeks earlier. 
The results follow the 94.5% efficacy rate that the Massachusetts-based pharma reported two weeks earlier. -
Moderna CEO Expects COVID Vaccine Approval By December
Moderna has one of the leading coronavirus vaccines currently in development, along with a treatment being co-developed by Pfizer and BioNTech. 
Moderna has one of the leading coronavirus vaccines currently in development, along with a treatment being co-developed by Pfizer and BioNTech. -
Moderna Candidate COVID Vaccine Shows Signs Of Being Effective In Older Patients
Nearly 80 percent of those who have died from the virus are older, researchers say. 
Nearly 80 percent of those who have died from the virus are older, researchers say. -
Moderna To Provide 160 Million Total Doses Of COVID Vaccine To EU
Moderna and the U.S. have sealed an agreement for the supply of around 100 million COVID-19 vaccines worth $1.5 billion. 
Moderna and the U.S. have sealed an agreement for the supply of around 100 million COVID-19 vaccines worth $1.5 billion. -
Moderna Plans To Sell COVID-19 Vaccine Doses For $32 to $37 Under Its 'Pandemic Pricing'
The company is currently in talks for bigger volume deals that will take vaccination costs for the public even lower. 
The company is currently in talks for bigger volume deals that will take vaccination costs for the public even lower. -
Moderna Stock Flounders After JPMorgan Downgrade, Despite COVID-19 Vaccine Hopes
The company's stock had risen 385 percent since the start of the year on hopes of a successfull COVID-19 vaccine. 
The company's stock had risen 385 percent since the start of the year on hopes of a successfull COVID-19 vaccine. -
Moderna Stock Climbs After COVID-19 Vaccine Shows Impressive Results In Trials
Stock settled at around $80 a share at the close Wednesday afternoon. 
Stock settled at around $80 a share at the close Wednesday afternoon.
